Effectiveness and safety of metoclopramide in treatment of intractable hiccup: a protocol of systematic review and meta-analysis

IntroductionHiccup is a common disease that not only occurred on adults but also on infants, which can severely do harm to patients’ physical and psychological health. Metoclopramide has been reported to have effects on intractable hiccup. However, there is a limited evidence that describes the effi...

Full description

Saved in:
Bibliographic Details
Published inBMJ open Vol. 12; no. 10; p. e059887
Main Authors Wang, Die, Zi, Changyan, Zhang, Baocheng, Wang, Baojia, Chen, Tao, Wang, Long, Gao, Yongxiang
Format Journal Article
LanguageEnglish
Published London British Medical Journal Publishing Group 06.10.2022
BMJ Publishing Group LTD
BMJ Publishing Group
SeriesProtocol
Subjects
Bias
Brain cancer
Cancer therapies
Drug dosages
Etiology
FDA approval
GASTROENTEROLOGY
Gastroenterology and Hepatology
Gastrointestinal diseases
INTERNAL MEDICINE
Meta-analysis
OTOLARYNGOLOGY
Patients
Systematic review
Online AccessGet full text

Cover

More Information
Summary:IntroductionHiccup is a common disease that not only occurred on adults but also on infants, which can severely do harm to patients’ physical and psychological health. Metoclopramide has been reported to have effects on intractable hiccup. However, there is a limited evidence that describes the efficacy and safety of metoclopramide in the treatment of intractable hiccup. The aim of this article is to obtain evidence on the effectiveness and safety of metoclopramide in treating patients with intractable hiccup.Methods and analysisWe will search the following databases, including PubMed, Cochrane Library, Embase, Web of Science, CBM, Wan-fang, VIP database, CNKI and MEDLINE from their inception to 11 November 2021. All the randomised controlled trials associated with metoclopramide in treating intractable hiccup will be included. Articles screened, selected and extracted will be performed by two researchers independently. The risk of bias will be assessed by using the Cochrane Collaboration. We will carry out the meta-analysis by using RevMan V.5.4 software.PROSPERO registration numberCRD42021293000.
Bibliography:Protocol
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2044-6055
2044-6055
DOI:10.1136/bmjopen-2021-059887